Page values for "Carbamazepine"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Carbamazepine
brand	`String`	Tegretol (IR, XR, suspension), Carbatrol (ER), Equetro (ER for bipolar), Epitol
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Anticonvulsants\|Anticonvulsant]] • [[:Category:Mood stabilizers\|Mood stabilizer]] • [[:Category:Sodium channel blockers\|Sodium channel blocker]]
mechanism	`String`
uses	`String`	'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"'
starting_dose	`String`	Seizures: 200 mg PO BID, titrate by 200 mg/week to 800-1200 mg/day. Trigeminal neuralgia: 100-200 mg BID, titrate to 200-400 mg TID. Bipolar: 200 mg BID, titrate to 1600 mg/day
preparations	`String`	IR tablets 200 mg; chewable 100 mg; oral suspension 100 mg/5 mL; XR tablets 100, 200, 400 mg (Tegretol XR); ER capsules 100, 200, 300 mg (Carbatrol, Equetro)
fda_max	`String`	1200 mg/day (adult seizures); 1600 mg/day (bipolar mania)
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Anticonvulsant effect within days; trigeminal neuralgia relief 24-72 hours; mood-stabilizing effect over weeks
duration	`String`	BID-QID dosing (IR); BID for ER formulations
halflife	`String`	'''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period'"`UNIQ--ref-0000001D-QINU`"'
bioavailability	`String`	~80% (oral)'"`UNIQ--ref-0000001E-QINU`"'
pregnancy	`String`	'''Substantial teratogenic risk''' including neural tube defects, craniofacial malformations, cardiac defects, and growth restriction; folic acid supplementation and effective contraception are required in reproductive-age patients'"`UNIQ--ref-0000001F-QINU`"'
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US